GlassScriptPhysician profile
Deanna Schroeder
NPI 1265523906
$6,461.94
in general payments reported to CMS, 2019-2025
49 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,681 · 2022: $1,442 · 2023: $916 · 2024: $1,194 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,307.41 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.33 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $758.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $739.63 | 2021-2025 | |
| Lilly USA, LLC | $441.68 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Otsuka America Pharmaceutical, INC. | $414.61 | 2021-2025 | Rexulti |
| Pfizer INC. | $296.62 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $284.62 | 2021-2022 | |
| Lundbeck LLC | $273.36 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.25 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $146.69 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.80 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $140.41 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $127.56 | 2021-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $112.02 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.61 | 2022-2025 | Caplyta |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $89.93 | 2021-2024 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $87.10 | 2022-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $86.61 | 2021-2023 | |
| Dexcom, INC. | $81.20 | 2021-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $78.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.94 | 2021-2022 | |
| Radius Health, INC. | $73.76 | 2025 | Tymlos |
| Abiomed | $58.07 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $56.13 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54.61 | 2021-2023 | Austedo |
| Amarin Pharma, INC. | $53.74 | 2021 | |
| Sobi, INC | $51.64 | 2021-2022 | |
| Alkermes, INC. | $50.21 | 2021-2023 | Vivitrol |
| Neurelis, INC. | $49.82 | 2024-2025 | Valtoco |
| Idorsia Pharmaceuticals US INC | $49.71 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $47.76 | 2023 | Auvelity |
| Corcept Therapeutics | $33.90 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $31.15 | 2023 | Inspire |
| Ani Pharmaceuticals, INC. | $30.89 | 2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $29.38 | 2024 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $27.86 | 2025 | Dupixent |
| Biohaven Pharmaceutical Holding Company LTD. | $26.31 | 2022 | |
| Sanofi Pasteur INC. | $25.99 | 2024 | |
| Ferring Pharmaceuticals INC. | $22.80 | 2023 | Rebyota |
| Boston Scientific Corporation | $20.27 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.17 | 2021 | |
| Renalytix Ai, INC. | $20.11 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Cranial Technologies, INC | $18.00 | 2025 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $17.57 | 2022 | |
| Agile Therapeutics, INC. | $16.89 | 2021 | |
| Vivus LLC | $16.66 | 2022 | |
| Edwards Lifesciences Corporation | $15.61 | 2022 | |
| Antares Pharma, INC. | $13.49 | 2023 | Xyosted, Tlando, Nocdurna |
| Allergan, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.